GEN Exclusives

More »

GEN News Highlights

More »
Apr 23, 2007

KaloBios Licenses Humaneering Technology to Novartis

  • KaloBios Pharmaceuticals’ granted Novartis a nonexclusive license its Humaneering™ technology. Novartis will use the platform to develop human antibodies.

    This is the first such nonexclusive technology transfer that KaloBios has offered for its Humaneering platform. As part of the transition plan, KaloBios has agreed to Humaneer three antibodies for Novartis in addition to the three that have been successfully completed as part of a pilot R&D relationship.

    "This nonexclusive license brings in sufficient new revenue to fund our clinical studies for KB001 (Pseudomonas infections) and our three clinical programs for KB002 (inflammation and autoimmune indications) into mid 2008," notes David Pritchard, KaloBios CEO.

    Humaneering is KaloBios’ method for converting nonhuman antibodies into engineered human antibodies for therapeutic drug applications. The system maintains epitope specificity and increases affinity, according to the company. The Humaneered antibodies are as close as, if not closer to, human germline sequences than the products of fully human antibody generation techniques.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?